Cite
HARVARD Citation
Thein, K. et al. (n.d.). 961PRisk of secondary hematological malignancies and hematological toxicities in recurrent ovarian cancer patients treated with poly adenosine diphosphate ribose polymerase (PARP) inhibitors maintenance. Annals of oncology. p. . [Online].